Aptargroup Stock Price, News & Analysis

AptarGroup, Inc. (NYSE: ATR) will host a virtual Capital Markets Day on September 10, 2021, starting at 9:00 a.m. EDT. Senior executives will present and participate in a Q&A session. Interested parties can access the event via the Investor Relations page. A replay will be available for 30 days post-event. Aptar is a leader in drug delivery and consumer product dispensing, operating in various markets such as pharmaceutical and beauty, with a workforce of 13,000 across 20 countries.

AptarGroup, Inc. (NYSE: ATR) announced the passing of Dr. Joanne Smith, a long-time member of its Board of Directors, who served since 1999. Dr. Smith was also the Chairwoman of the Corporate Governance Committee and was revered for her deep market insights and leadership style. Her contributions significantly impacted Aptar's success over the past 22 years, as noted by Chairman George Fotiades and President & CEO Stephan B. Tanda. The company appreciates her guidance and expresses deep gratitude for her commitment.

AptarGroup, Inc. (NYSE: ATR) has successfully acquired a majority stake of approximately 64.6% in Voluntis for €8.70 per share. Following this acquisition, Aptar will initiate a mandatory cash tender offer for the remaining shares at the same price. The transaction has received approval from the French Ministry of Economy and is expected to enhance Aptar's position in drug delivery solutions.

The company's board will issue an opinion on the tender offer, guided by an independent expert report. The current management of Voluntis is expected to remain post-acquisition.

AptarGroup, Inc. (ATR) reported second quarter 2021 results, with sales increasing 16% to $811 million, driven by strong core sales growth across segments. Core sales rose by 10%, particularly in Beauty + Home and Food + Beverage. Net income was $55 million, up 32% year-over-year. Earnings per share reached $0.81, a 29% increase. However, cash flow from operations dropped 23% to $176 million, and free cash flow decreased 63%. The company announced a share purchase agreement for Voluntis and a strategic collaboration with YAT. For Q3 2021, Aptar expects gradual improvement in operating results amidst ongoing cost pressures.

AptarGroup, Inc. (NYSE: ATR) has announced its plan to acquire 80% of Weihai Hengyu Medical Products Co., Ltd., a notable Chinese manufacturer of elastomeric and plastic components for injectable drug delivery. This strategic investment aims to enhance Aptar's capabilities in high-growth markets like China while responding to local market demands. The acquisition is expected to close by the end of Q3 2021 and is not projected to materially impact adjusted earnings per share for 2021 or 2022. This move aligns with Aptar's ongoing strategy to strengthen its position in the injectable drug delivery market.

AptarGroup, Inc. (NYSE: ATR) has acquired a majority stake in Voluntis, acquiring approximately 64.6% of its share capital at €8.70 per share. The share purchase agreement was signed on July 22, 2021, following exclusive negotiations since June 21, 2021. The acquisition is subject to customary conditions and expected to complete by the end of Q3 2021. Following the acquisition, Aptar plans a mandatory cash tender offer for remaining Voluntis shares at the same price, pending regulatory approval. Voluntis’ board has appointed an independent expert to review the offer's financial terms.

AptarGroup, Inc. (NYSE: ATR) has announced a quarterly cash dividend of $0.38 per share, payable on August 25, 2021, to stockholders of record as of August 4, 2021. The company, a leader in drug delivery and consumer product dispensing solutions, will also hold a conference call on July 30, 2021 at 8:00 a.m. Central Time to discuss its second quarter results for 2021. Interested parties can access the live call via a webcast on their Investors page.

AptarGroup (NYSE: ATR) and YAT have announced a strategic collaboration to develop innovative skincare products. This partnership combines YAT's consumer-centric approach and market insights with Aptar’s advanced packaging solutions. By leveraging their combined expertise, they aim to enhance product offerings in China, catering to specific consumer skincare needs. Aptar has also made a strategic equity investment in YAT to further support the development of tailored solutions in this fast-growing market.

AptarGroup, Inc. (NYSE: ATR) has entered exclusive negotiations to potentially acquire all outstanding shares of Voluntis (ENXTPA: ALVTX) for €8.70 per share, valuing the company at approximately €78.8 million ($95.3 million). The acquisition aims to enhance Aptar's digital health portfolio by integrating Voluntis's digital therapeutic solutions, which support chronic disease management. This strategic move aligns with Aptar's focus on expanding digital capabilities and is expected to have a dilutive impact of $0.01 to $0.02 per share for FY 2022.